Zhejiang CONBA Pharmaceutical Co., Ltd.SSE: 600572

(600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Receipt of Drug Registration Certificate for Dapoxetine Hydrochloride Tablets by Subsidiary

· Issued by Zhejiang CONBA Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600572 · · 2 pages · Chinese

Summary by 6ix AI

Zhejiang CONBA Pharmaceutical Co., Ltd. announced that its subsidiary has received a drug registration certificate for Dapoxetine Hydrochloride Tablets from the National Medical Products Administration. The certificate covers two specifications of the drug, which is indicated for the treatment of premature ejaculation in men. The company has invested significantly in the research and development of this product, which is expected to positively impact its performance. However, the future market sales and revenue are subject to various uncertainties, including national policies and market competition.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600572zhejiang-conba-pharmaceutical-co-ltdannouncement-on-receipt-of-drug-registration-certificate-for-dapoxetine-hydrochloride-tablets-by-subsidiary

Release

Announcement on Receipt of Drug Registration Certificate for Dapoxetine Hydrochloride Tablets by Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Zhejiang CONBA Pharmaceutical

Later from Zhejiang CONBA Pharmaceutical

All Zhejiang CONBA Pharmaceutical news releases